Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05139615 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT05139615 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 22 participants.
The verdict
NCT05139615, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, pharmacokinetics, and effect on cardiac function of intravenous APD418 in adult participants with heart failure with reduced ejection fraction (HFrEF).
Interventions
- DRUG Placebo
- DRUG APD418
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-12-28 |
| Est. Completion | 2022-09-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05139615
The ClinicalTrials.gov registry entry for NCT05139615 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05139615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05139615 about?
NCT05139615 is a clinical study titled "A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction". The purpose of this study is to evaluate the safety, pharmacokinetics, and effect on cardiac function of intravenous APD418 in adult participants with heart failure with reduced ejection fraction (HFrEF).
What is the current status of trial NCT05139615?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2021-12-28. Estimated completion is 2022-09-19.
What interventions are being tested in trial NCT05139615?
The interventions under investigation include: Placebo (DRUG), APD418 (DRUG).
Who is sponsoring clinical trial NCT05139615?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.